Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients
Executive Summary
Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16
You may also be interested in...
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting
Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy
The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication